1. Pludowski P, Holick MF, Pilz S, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality: a review of recent evidence. Autoimmun Rev 2013;12:976–989.
3. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006;92:49–59.
4. Bhalla AK, Amento EP, Krane SM. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol 1986;98:311–322.
5. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173:2909–2912.
6. Hong JY, Kim SY, Chung KS, et al. Association between vitamin D deficiency and tuberculosis in a Korean population. Int J Tuberc Lung Dis 2014;18:73–78.
11. Stavroulopoulos A, Cassidy MJ, Porter CJ, Hosking DJ, Roe SD. Vitamin D status in renal transplant recipients. Am J Transplant 2007;7:2546–2552.
13. Falkiewicz K, Boratynska M, Speichert-Bidzinska B, et al. 1,25-dihydroxyvitamin D deficiency predicts poorer outcome after renal transplantation. Transplant Proc 2009;41:3002–3005.
14. Ducloux D, Courivaud C, Bamoulid J, Kazory A, Dumoulin G, Chalopin JM. Pretransplant serum vitamin D levels and risk of cancer after renal transplantation. Transplantation 2008;85:1755–1759.
15. Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Transplant 2005;19:230–235.
16. Ariza-Heredia EJ, Beam EN, Lesnick TG, Cosio FG, Kremers WK, Razonable RR. Impact of urinary tract infection on allograft function after kidney transplantation. Clin Transplant 2014;28:683–690.
17. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–281.
21. Marcen R, Jimenez S, Fernandez-Rodriguez A, et al. Are low levels of 25-hydroxyvitamin D a risk factor for cardiovascular diseases or malignancies in renal transplantation? Nephrol Dial Transplant 2012;27 Suppl 4:iv47–iv52.
22. Kanter Berga J, Crespo Albiach J, Beltran Catalan S, et al. Vitamin D deficiency in a renal transplant population: safe repletion with moderate doses of calcidiol. Transplant Proc 2010;42:2917–2920.
24. Eyal O, Aharon M, Safadi R, Elhalel MD. Serum vitamin D levels in kidney transplant recipients: the importance of an immunosuppression regimen and sun exposure. Isr Med Assoc J 2013;15:628–633.
25. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429–435.
27. Clayton P, Singer R. 25-Hydroxyvitamin D levels in prevalent Australian dialysis patients. Nephrology (Carlton) 2009;14:554–559.
28. Elder GJ. Vitamin D levels, bone turnover and bone mineral density show seasonal variation in patients with chronic kidney disease stage 5. Nephrology (Carlton) 2007;12:90–94.
29. Lim JH, Cho JH, Lee JH, et al. Risk factors for recurrent urinary tract infection in kidney transplant recipients. Transplant Proc 2013;45:1584–1589.
33. Sezer S, Yavuz D, Canoz MB, Ozdemir FN, Haberal M. Vitamin D status, bone mineral density, and inflammation in kidney transplantation patients. Transplant Proc 2009;41:2823–2825.
34. Courbebaisse M, Xu-Dubois YC, Thervet E, et al. Cholecalciferol supplementation does not protect against renal allograft structural and functional deterioration: a retrospective study. Transplantation 2011;91:207–212.
35. Ozdemir BH, Ozdemir AA, Sezer S, Colak T, Haberal M. Influence of 1,25-dihydroxyvitamin D3 on human leukocyte antigen-DR expression, macrophage infiltration, and graft survival in renal allografts. Transplant Proc 2011;43:500–503.
36. Tanaci N, Karakose H, Guvener N, Tutuncu NB, Colak T, Haberal M. Influence of 1,25-dihydroxyvitamin D3 as an immunomodulator in renal transplant recipients: a retrospective cohort study. Transplant Proc 2003;35:2885–2887.
37. Uyar M, Sezer S, Arat Z, Elsurer R, Ozdemir FN, Haberal M. 1,25-Dihydroxyvitamin D(3) therapy is protective for renal function and prevents hyperparathyroidism in renal allograft recipients. Transplant Proc 2006;38:2069–2073.